We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
GlaxoSmithKline (GSK) has upgraded its full year (FY) 2018 guidance after recording growth in sales, margins and cash flow in its financial report for the second quarter (Q2) of 2018.